Gossamer Bio
About Gossamer Bio
Gossamer Bio is a San Diego-based company focused on the discovery and development of novel and differentiated therapeutic products, to address high unmet needs amongst various targeted patient populations. Founded by the former Receptos executive team, Gossamer Bio’s strategy will be to leverage an asset-rich in-licensing environment, with a focus on areas of high unmet need, utilizing a team with a strong track record of execution in immunology, inflammation, fibrosis and oncology.
YEAR FOUNDED:
2018
LEADERSHIP:
Founders and CEO: Faheem Hasnain
Founder and COO: Sheila Gujrathi, M.D
81 articles with Gossamer Bio
-
You have to give San Diego-based Gossamer Bio credit for the way it’s adapted its plans for an initial public offering (IPO) to deal with the government shutdown.
-
A summary of IPOs from companies in the biotech and pharma world since January 1, 2019.
-
Gossamer Bio Announces Updates Regarding its Initial Public Offering
1/30/2019
Gossamer Bio, Inc. announced that it has filed an amended registration statement on Form S-1 with the U.S. Securities and Exchange Commission in connection with its proposed initial public offering of its common stock.
-
Numerous biotech companies had filed for initial public offerings (IPOs) during the five-week government shutdown, but were unlikely to actually be able to be listed until the U.S. Securities and Exchange Commission (SEC) had a chance to review their filings.
-
San Diego-based Gossamer Bio is pulling the trigger on an initial public offering by harnessing a legal loophole that will allow the company to move forward with its listing plans despite the partial government shutdown, now in its 34th day.
-
Gossamer Bio Announces Commencement of Initial Public Offering
1/23/2019
Gossamer Bio, Inc. today announced that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (the “SEC”) in connection with the commencement of a proposed initial public offering of its common stock.
-
BioSpace is proud to present its NextGen Bio “Class of 2019,” a list of 20 up-and-coming life science companies in North America that launched* no earlier than 2017.
-
A summary of IPOs from companies in the biotech and pharma world since December 1, 2018.
-
Gossamer Bio, headquartered in San Diego, announced plans for its initial public offering (IPO) just before Christmas.
-
7 Biotech Trends to Look Out for in 2019
12/26/2018
As 2018 comes to a close, analysts, journalists, investors and industry-watchers are studying their crystal balls to see what trends to watch in the upcoming year. Here are 7 trends most likely to be hitting the news cycle. -
Gossamer Bio Announces Appointment of New Independent Directors
12/19/2018
Gossamer Bio, a privately held, clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced the appointment of Joshua H. Bilenker, M.D., Russell J. Cox and Renée Galá to its Board of Directors.
-
Gossamer Bio Announces Appointment of Jakob Dupont, M.D. as Chief Medical Officer
12/17/2018
Dr. Dupont, former Vice President in the Oncology Development Group at Genentech/Roche, will lead company’s clinical development
-
FierceBiotech Names Gossamer Bio as One of its “Fierce 15” Biotech Companies of 2018
10/2/2018
The Fierce 15 celebrates the spirit of being “fierce” – championing innovation and creativity, even in the face of intense competition.
-
Movers and Shakers for Sept. 10
9/10/2018
Let's take a look at who made a splash in the pharma and biotech world the past week. -
Gossamer Bio Announces $230 Million Series B Financing
7/23/2018
Gossamer Bio Inc. (“Gossamer Bio”), today announced the closing of a $230 million Series B.
-
Since it first launched with $100 million in the bank earlier this year, Gossamer Bio has been on something of a roll.
-
Aerpio Announces Exclusive License Agreement with Gossamer Bio for AKB-4924, a First in Class Hypoxia-Inducible Factor-1 Alpha Stabilizer in Development for Inflammatory Bowel Disease
6/25/2018
The arrangement combines Aerpio’s deep understanding of HIF biology with Gossamer’s experience in inflammation, immunology and inflammatory bowel disease (IBD) drug development.
-
This morning two companies announced deals that will yield potential benefits to multiple patient populations.
-
Gossamer Bio Announces Appointment of Bryan Giraudo as Chief Financial Officer
4/25/2018
Mr. Giraudo will lead the company’s finance and administrative functions.
-
The Latest Biotech Startups to Watch
1/8/2018
A look at the latest startups that have emerged in 2018 so far.